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Theblood–brainbarrier is ahighly selective anatomical and functional interface allowingaunique environment forneuro-glianetworks.
Blood–brain barrier dysfunction is common in most brain disorders and is associated with disease course and delayed complications.
However, the mechanisms underlying blood–brain barrier opening are poorly understood. Here we demonstrate the role of the neu-
rotransmitter glutamate in modulating early barrier permeability in vivo. Using intravital microscopy, we show that recurrent seizures
and the associated excessive glutamate release lead to increased vascular permeability in the rat cerebral cortex, through activation of
NMDA receptors. NMDA receptor antagonists reduce barrier permeability in the peri-ischemic brain, whereas neuronal activation using
high-intensity magnetic stimulation increases barrier permeability and facilitates drug delivery. Finally, we conducted a double-blind
clinical trial in patients with malignant glial tumors, using contrast-enhanced magnetic resonance imaging to quantitatively assess
blood–brain barrier permeability.We demonstrate the safety of stimulation that efficiently increased blood–brain barrier permeability
in 10 of 15 patients with malignant glial tumors. We suggest a novel mechanism for the bidirectional modulation of brain vascular
permeability toward increased drug delivery and prevention of delayed complications in brain disorders.
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Introduction
The blood–brain barrier (BBB) is a highly specialized interface
that separates the circulating blood from the extracellular fluid in
the brain in theCNS. TheBBB is formed at the level of endothelial
cells, which are connected by tight-junction protein complexes
that seal together the paracellular space. It consists of specialized
transcellular transport systems, a basal membrane, and astrocytic
end feet (Abbott et al., 2006). The selective nature of the BBB
allows the formation of a unique extracellularmilieuwithin brain
neuropil (Abbott et al., 2006), essential for normal brain func-
tion. In most common brain disorders, including epilepsy, trau-
matic brain injury, stroke, and neurodegenerative diseases, the
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Significance Statement
In this study,we reveal a newmechanism that governs blood–brain barrier (BBB) function in the rat cerebral cortex, and, byusing
the discovered mechanism, we demonstrate bidirectional control over brain endothelial permeability. Obviously, the clinical
potential of manipulating BBB permeability for neuroprotection and drug delivery is immense, as we show in preclinical
and proof-of-concept clinical studies. This study addresses an unmet need to induce transient BBB opening for drug delivery in
patients with malignant brain tumors and effectively facilitate BBB closure in neurological disorders.
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BBB may be compromised (Benveniste et al., 1984; Nishizawa,
2001; Brown and Davis, 2002; Davies, 2002; Seiffert et al., 2004;
van Vliet et al., 2007; Friedman, 2011) and could contribute to
neural dysfunction, neural network reorganization, and degener-
ation, thus modifying disease progression (Benveniste et al.,
1984; Seiffert et al., 2004; van Vliet et al., 2007; Tomkins et al.,
2008). However, themechanisms underlying BBB dysfunction in
brain disorders are not fully understood.
The potential of excessive neuronal activation to increase
brain vascular permeability to blood constituents is supported by
the following indirect evidence: (1) seizures, and in particular
when recurrent or prolonged, such as in status epilepticus (SE),
are associated with BBB dysfunction (Nitsch andHubauer, 1986;
Friedman, 2011); (2) increased BBB permeability is often a
hallmark of the perilesional brain in ischemia, trauma, and tu-
mors, neurological conditions associated with neuronal hyper-
excitability, epileptic seizures, and spreading depolarizations
(Davies, 2002; Tomkins et al., 2008; Schoknecht et al., 2014); (3)
themajor excitatory neurotransmitter, glutamate, has been dem-
onstrated to increase permeability in cultured brain endothelial
cells (Sharp et al., 2003; Andra´s et al., 2007); and (4) whole-brain
stimulation, such as that performed during electroconvulsive
treatment for severe depression, has been shown to accompany
increased glutamate levels (Zangen and Hyodo, 2002) and BBB
breakdown (Mottaghy et al., 2003). Therefore, we tested the hy-
pothesis that hypersynchronized neuronal activation and exces-
sive accumulation of extracellular glutamate (Bradford, 1995)
result in BBB dysfunction.
Materials andMethods
Animal handling.All experimental procedures in animals were approved
by the Ben-Gurion University ethics committee for animal testing. Un-
less otherwise mentioned, all materials were purchased from Sigma-
Aldrich. Surgical procedures in male Sprague Dawley rats (200–380 g
bodyweight) were performed as reported previously (Prager et al., 2010).
Rats were deeply anesthetized by intraperitoneal administration of ket-
amine (100 mg/ml, 0.08 ml/100 g) and xylazine (20 mg/ml, 0.06 ml/100
g) or oxygen-enriched isoflurane (1–1.5%) inhalation for 3 h as de-
tailed in Results. The tail vein was catheterized, and animals were placed
in a stereotactic frame (Fig. 1A) under a SteREOLumar V12 fluorescence
microscope (Zeiss). Body temperature was continuously monitored and
kept stable at 37 0.5°C using a feedback-controlled heating pad (Physi-
temp). Heart rate, breath rate, and oxygen saturation levels were contin-
uously monitored using MouseOx (STARR Life Sciences). A cranial
section (4 mm caudal, 2 mm frontal, 5 mm lateral to bregma) was re-
moved over the right sensorimotor cortex. The dura and arachnoid layers
were removed (Fig. 1B), and the exposed cortex was continuously per-
fused with artificial CSF (ACSF; Prager et al., 2010) containing the fol-
lowing (in mM): 124 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 2 MgSO4, 2
CaCl2, 3 KCl, and 10 glucose, pH 7.4. To block neuronal activity, tetro-
dotoxin (TTX; 10 M; Narahashi et al., 1964), 6-cyano-2,3-dihy-
droxy-7-nitro-quinoxaline (CNQX; 50 M; Yoshiyama et al., 1995),
D-()-2-amino-5-phosphonopentanoic acid (D-AP-5; 50 M; Morris,
1989), and picrotoxin (PTX; 50 M; Yoon et al., 1993) were added to the
ACSF. To induce prolonged seizures (SE), 4-aminopyridine (4-AP; 500
M; Uva et al., 2013) or PTX (100 M) were added to the ACSF. Electro-
corticogram (ECoG) was recorded using bipolar electrodes and a telem-
etric recording system (Data System International). In some cases,
thrombotic stroke was induced using photothrombosis (Watson et al.,
1987). Detection of calcium ions in the rat cortex was done with calcium
chelators as reported previously (Stosiek et al., 2003): 50 g of the fluo-
rescent chelator Oregon green-BAPTA-1AM (OGB; Life Technologies)
were dissolved in 4 l of dimethylsulfoxide (DMSO) containing 20%
pluronic F-127. This mixture was diluted in 36 l of a loading solution
containing the following (in mM): 150 NaCl, 2.5 KCl, and 10 HEPES in
ddH2O, pH 7.4. The exposed cortex was incubated with the finalmixture
Figure1. Direct cortical imaging in anesthetized rodents is analyzed for quantitative assessment of BBBpermeability.A, A rat is anesthetized andplaced in a stereotactic frame (seeMaterials and
Methods).B, Craniotomy is used to expose the neocortex (seeMaterials andMethods). C, Cortical surface following injection of NaFlu.D, Rescaling and segmentation of the fluorescence image. The
product is a binary image inwhich vascular and extravascular areas are contrasted. E, Averaging pixel intensities through time in the primary artery (marked by red frame in C) forms theAIF (primary
artery, red). Each extravascular pixel is also represented by an IT curve (extravascular, black). Tracer residues in extravascular space are assessed by comparing both functions in themarked time span
(arrow). The result is a per-pixel numerical parameter reflective of BBB permeability level (PI). F, Spatial mapping of BBB permeability.
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for 1 h. Detection of nitric oxide (NO) ions was done with the NO sensor
4-amino-5-methylamino-2,7-difluorofluorescein diacetate (DAF-FM;
Life Technologies; Schoknecht et al., 2014). A stock solution (1 mM in
DMSO) was diluted to 200 M in ACSF and mounted on the exposed
cortex for 30 min. Probe-based confocal laser microscopy (PCLM) was
performed using Cellvizio dual band (Mauna Kea Technologies) at 488
and 660 nm and analyzed with in-house developedMATLAB scripts. For
drug delivery experiments, penicillin G sodium was administered intra-
venously (0.833MU/kg in 0.9%NaCl). In some cases, oxygen levels were
measured in brain parenchyma using a miniaturized Clark-type oxygen
glass-microsensor (UNISENSE), positioned within the parenchyma, ad-
jacent to the selected arteriole for continuous monitoring.
Fluorescent angiography and BBB permeability assessment. Dynamic
imaging of regional cerebral blood flow and BBB permeability measure-
ments were performed as reported previously (Prager et al., 2010;
Schoknecht et al., 2014; Chassidim et al., 2015) with minor adds-on to
the image analysis methods. The non-BBB permeable fluorescent dye
sodium fluorescein (NaFlu) was injected intravenously (1 mg/ml, 0.2
ml/injection, in 0.9%NaCl). Full-resolution (658 496 pixel) images of
cortical surface vessels were obtained (5 frames/s, EMCCD camera, DL-
658 M-TIL; Andor Technology; Fig. 1C) before, during, and after injec-
tion of the tracer. Offline image analysis was performed using MATLAB
(MathWorks) and included subpixel image registration, segmentation
using noise filtration, hole-filling and adaptive threshold to produce a
binary image, and separating blood vessels from extravascular regions
(Fig. 1D). Signal intensity changes over time and space were then ana-
lyzed so that each pixel was represented by intensity versus time (IT)
curve (Fig. 1E). An arterial IT curve [arterial input function (AIF)] was
created by spatially averaging signal intensity through time in the pri-
mary artery. A BBB permeability index (PI) was calculated for each ex-
travascular pixel as the ratio between IT curve and AIF, from the point of
the second decline phase to the end of the measurement (250–300 s,
Fig. 1E): PI 
1
T
tcr
tend IEV
IAIF
tdt, whereT	 tend tcr. The PI indicates how
much tracer remains in extravascular tissue in relation to the applied
amount. PI
 1 indicates tracer accumulation and defines BBB dysfunc-
tion. Fitting a PI to each extravascular pixel enabled spatial mapping of
BBB permeability (Fig. 1F ). The PI for each vascular pixel was set to 0,
and therefore vessels were excluded from the map. The global permea-
bility of a region was calculated by averaging its PI values. Permeability
measurements with this approach are possible only for regions with fully
functional vasculature as the transfer of molecules between vessel and
parenchyma is quantified. Increased permeability in damaged vessels is
not depicted here. The method was validated in well established models
of BBB dysfunction such as cortical perfusion of sodium deoxycholate
and photo-induced stroke (Prager et al., 2010; Schoknecht et al., 2014;
Chassidim et al., 2015). Additionally, qualitative assessment of BBB per-
meability was done by intravenously injecting the albumin-binding dye
Evans blue (EB; 1 mg/ml, 2.4 ml/kg, in 0.9%NaCl;Wolman et al., 1981),
extraction of brains after cardiac perfusion (4% paraformaldehyde in
PBS), and verifying extravasation of the dye. Assessments of vascular
diameter in the exposed cortical sectionwere performed by transforming
vascular pixel quantification into metric measurements.
Transcranial magnetic stimulation. Repetitive transcranial magnetic
stimulation (rTMS) was applied to the exposed cortex of the rat using a
Rapid2 stimulator (Magstim) and a conventional circular coil (58 mm
outer diameter, 56 mm inner diameter, 1.5 mm thickness, 18.4 H in-
ductance; Brainsway; Gersner et al., 2011) at either 1 or 10 Hz and as real
or sham. Two stimulation protocols were applied: (1) low frequency: 1
Hz, 50 s pulse duration; duration, 50 s train; intertrain interval, 60 s;
number of trains, 5; total number of pulses, 250; and (2) high frequency:
10 Hz, 50 s pulse duration; train duration, 1 s; intertrain interval, 9 s;
number of trains, 5; trains were repeated 5 times with 60 s intervals; total
number of pulses, 250. In both protocols, stimulation intensity was set to
130% of resting motor threshold (RMT; the minimal intensity required
to initiate a motor response indicated by contralateral paw/whisker mo-
tion). Sham stimulation was applied by placing a coil in the same loca-
tion, above the exposed cortex, while stimulating a second coil, placed at
a distance of 100–120 cm away from the skull. Sham stimulation did not
evoke any motor response. BBB permeability analysis was performed
before and after stimulation.
Thrombotic stroke. The photo-reactive substance, rose bengal (RB; 7.5
mg/ml in 0.9%NaCl, 0.133ml/100 g), was injected into the tail veinwhile
a vascular region in the exposed cortex was laser illuminated at 523 nm (5
mW;CNI Lasers). The transformation of RB into free radicals, binding to
platelets, and the formation of clots occurredwithin 15min (Prager et al.,
2010; Schoknecht et al., 2014).
ECoG recording and analysis. ECoG was recorded using a telemetric
system (Data System International). Two electrodes were implanted, one
attached to an intracranial screw adjacent to the exposed cortex and the
second placed over the exposed cortex while secured with bone wax
(Ethicon) and dental cement (GC America). In-house MATLAB scripts
were used to display and record signals for post-processing. Signals were
sampled at 200 Hz and filtered using a MATLAB simulated Butterworth
filter to display only the desired frequency band (10–40 Hz). The mean
power was calculated using the MATLAB “pwelch” function.
Patient monitoring. The human trial was approved by the local ethics
committee at La-SapienzaUniversity, Rome, Italy. All patients gave writ-
ten consent for participation in the trial. A total of 15 subjects (aged
32–76 years, 10 males) with histologically confirmed glioblastoma mul-
tiform (GBM, grade IV) were enrolled for a short pilot study. Patients
with cardiac pacemakers, neurostimulators, pumps, or medical or surgi-
cal clips were excluded. All subjects underwent previous surgery (crani-
otomy with gross tumor resection) at least 6 months before the study.
Patient characteristics are listed in Table 1. After resection, subjects un-
derwent standard postoperative treatment with radiotherapy, followed
Table 1. Clinical characteristics of patients
Subject ID Gender Age (years) Date of operation Tumor site Side Anti-epileptic drugs at present KPS Phase of disease
1 M 70 03/07/2010 FPO L No 70 Progression
2 M 76 14/09/2006 O L Yes 90 Stable
3 M 53 08/03/2010 P L Yes 100 Stable
4 M 47 17/05/2010 P R Yes 100 Stable
5 F 41 24/09/2008 F L No 100 Stable
6 M 48 23/10/2007 P R Yes 100 Stable
7 M 62 04/04/2007 O L Yes 100 Stable
8 F 63 28/11/2009 TO R Yes 100 Stable
9 M 36 04/08/2010 FTP L Yes 100 Stable
10 F 32 21/10/2010 FT L Yes 100 Stable
11 M 54 09/12/2010 T L Yes 100 Stable
12 M 71 27/11/2008 TP R Yes 90 Stable
13 F 59 21/07/2010 F R Yes 100 Stable
14 F 73 12/10/2010 T L Yes 100 Stable
15 M 56 06/11/2009 T L No 90 Stable
Age of subjects at time of study is listed. Tumor site: F, frontal; O, occipital; P, parietal; T, temporal; R, right; L, left; KPS, Karnofsky performance status.
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by adjuvant chemotherapy using temozolomide. At the time of the study,
subjects were in a stable condition and were not on steroid medication.
Treatment protocols were not modified during the study. In addition,
four non-tumor control subjects were recruited from alternative deep
TMS (dTMS) trials (pain and aphasia) that were taking place at the same
hospital (aged 26–56 years, threemales). Subjects were analyzed for BBB
permeability using dynamic contrast-enhanced magnetic resonance im-
aging (DCE-MRI; Chassidim et al., 2013; see Fig. 6).
Magnetic resonance imaging for BBB permeability assessment. Imaging
was performed with a 1.5 T Intera scanner (Phillips Healthcare) contain-
ing a six-element receiver coil. A standard battery of anatomical scans
was performed during the prestimulation session. These scans included
diffusion-weighted imaging, fluid-attenuated inversion recovery, T2-
weighted scans, and a high-resolution T1-weighted anatomical scan (3D
gradient echo; TR, 8.6 ms; TE, 3.5 ms; TI, 900 ms; FOV, 240 240 mm;
matrix, 256 256; slice thickness, 1.2 mm; 150 slices; flip angle, 8°). In
addition, two baseline scans were performed with DCE-MRI (spin echo;
TR, 1000 ms; TE, 8 ms; FOV, 240  180 mm; matrix, 256  192; slice
thickness, 3 mm with no gap; 42 slices; two concatenations; acquisition
time, 3 min, 14 s). The DCE-MRI acquisition consisted of at least seven
longitudinal scans using the same protocol. Images were processed using
Statistical Parametric Mapping (SPM; MATLAB; http://www.fil.ion.ucl.
ac.uk/spm), FSL (for FMRIB Software Library; Functional MRI of the
Brain), NIH ImageJ (National Institutes of Health), and in-house scripts
created with MATLAB. Preprocessing was performed using SPM and
included coregistration, segmentation, spatial normalization, and
Gaussian smoothing with a 2  2  6 (x, y, z) mm kernel. Because of
difficulties in performing stimulation within the scanner, contrast agent
(gadopentetic acid, gadolinium-diethylenetriamine pentaacetic acid, 10
ml,Magnevist; Bayer)was injected at the end of stimulation, and imaging
started 3–5 min later. As a result, pharmacokinetic models that require
AIF measurement, e.g., the widely used Tofts model (Tofts, 1997), could
not be used. Therefore, a simplified form of DCE-MRI analysis was used
as recently published (Chassidim et al., 2013, 2015; Veksler et al., 2014).
To enable intrasubject and intersubject comparisons and compensate for
potential differences in injection and blood flow, slope maps were nor-
malized by dividing each voxel by the mean slope value in a region of
interest drawn in the superior sagittal sinus: slˆt 	 slt/slsag, where sl is
slope, t is tissue, and sag is superior sagittal sinus, respectively (Chassidim
et al., 2013). Subsequent analysis was restricted to voxels assigned as gray
or white matter components from segmentation of the high-resolution
anatomical scan. The upper limit of normal vascular permeability was
calculated using the cumulative distribution function (CDF) of the
tissue-masked slope maps. These were derived from the slope values of
the hemisphere contralateral to the resected tumor and both hemi-
spheres for the control group, in both cases after “sham” stimulation. The
95th percentile of the combined CDF was defined as the threshold. The
following masks of anatomical areas of interest were created and used to
measure permeability values: tumor bed, peritumoral area, contralateral
hemisphere, and ipsilateral hemisphere relative to the tumor (the latter
region excluding the tumor bed; see Fig. 7C). Note that the term “tumor
bed” is used interchangeably with the region corresponding to the re-
sected tumor zone. Themask of the tumor bed was created by tracing the
resected tumor outline on each slice of both the high-resolution anatom-
ical scan and the first DCE-MRI scan after sham stimulation. The con-
junction of these two masks was then defined as the tumor bed. The
peritumoral region was created by subtraction of the tumor bed mask
from a dilated tumor bed mask (created in FSL by mean dilation of
nonzero voxels). For each mask of every scan, two parameters were cal-
culated: (1) the mean value of the slope map; and (2) the percentage of
voxels with abnormally high slope values [suprathreshold (ST)]. Exam-
ination of the effect on BBB permeability was performed using these two
parameters. Slope differences were calculated as 100 (sl1 sl2)/sl2.
dTMS. dTMSwas delivered to human subjects at 1 Hz, on the anterior
periphery of the resected tumor bed using the newly designed H-coil
(Brainsway; Zangen et al., 2005; Roth et al., 2007) placed inside a special-
ized helmet. Human subjects presented on 2 consecutive days to receive
dTMS, followed byDCE-MRI. The stimulation location on the scalp was
selected on the first day after examination of the subject’s previous neu-
roimaging and in consultation with the treating oncologist, with the aim
of consistently selecting an area on the anterior periphery of the resected
tumor bed. The integrated coil design included an additional, indepen-
dent “sham” coil that produces no significant level of cortical stimulation
but reproduces a similar degree of auditory and scalp sensations as the
“real” dTMS coil. Choice of real/sham was done via switch in the stimu-
lation apparatus. Stimulationwas performed each day using either real or
sham coils, with the patients and operators blinded to the choice. The
order of stimulation was counterbalanced across subjects. The focal
point of the coil was marked on the scalp with MRI-visible fiducials. A
radio frequency identification card-based system controlled blinded
switching between the coils. Comparison of BBB permeability was done
between post-real and post-sham states. For each patient, RMT was de-
termined before each treatment with the coil placed on the hand area of
themotor cortex ipsilateral to the stimulation site (Roth et al., 2007). The
RMTwas defined as the lowest TMS intensity capable of evoking amotor
reaction in the thumb as determined by a combination of visual inspec-
tion and electromyogram recording of the abductor pollicis brevis mus-
cle. Stimulation parameters were defined based on the animal study
results and safety protocols (Rossi et al., 2009) and were as follows: fre-
quency, 1 Hz; pulse duration, 360 s; train duration, 50 s; intertrain
interval, 60 s; number of trains, 5; total number of pulses, 250; stimula-
tion intensity, 130% of RMT. The consistent positioning of the stimula-
tion coil on the intended target location was facilitated by the use of a
simple device developed in-house, based on the touching together of two
small metal contacts placed on the coil focus and the stimulation loca-
tion, respectively. A flash of an LED and an audible buzz indicated the
correct positioning.
Experimental design. No blinding was performed in animal studies.
Naive animals were randomly selected for treatment. Data were analyzed
identically (regardless of treatment selection) usingMATLAB algorithms
developed in-house and validated in advance. Human patients and op-
erators were blinded to the choice of sham versus real dTMS.
Statistical analysis. Unless otherwise mentioned, mean  SEM are
given. All comparisons weremade using two-tailedMann–WhitneyU or
Wilcoxon’s rank-sum tests (Mann–Whitney or Wilcoxon in text). p 	
0.05 was defined as the level of significance. Statistical analysis was per-
formed using SPSS (IBM).
Results
Seizures result in BBB opening
We first tested whether focally induced cortical seizures are asso-
ciated with increased vascular permeability. Under deep anesthe-
sia (ketamine and xylazine; see Materials and Methods), we used
intravital microscopy and the open-window method (Fig. 1) for
simultaneous vascular imaging and ECoG recording. Recurrent
seizures were induced using local application of the potassium
channel blocker 4-AP, or blocker of the GABAA receptor, PTX
(n	 6 and n	 2, respectively). We quantitatively assessed BBB
integrity by analyzing angiographic fluorescence imaging data
(Prager et al., 2010; Fig. 1). Seizures were accompanied by a sig-
nificant immediate increase in vessel diameter (10.05  1.01%,
n 	 8, p 	 0.01, Wilcoxon; Fig. 2A,B). Vessel permeability to
NaFlu increased as soon as10min from seizure onset (20.01
7.24%, n 	 8, p 	 0.01, Wilcoxon; Fig. 2C,E,F) and remained
elevated during recurrent seizures (30 min from seizure onset
permeability increased by 14.17 4.65%, n	 7, p	 0.02, Wil-
coxon; Fig. 2F). To rule out ischemia as an underlying cause for
increased endothelial permeability, we measured tissue oxygen
levels during seizures using oxygen glassmicroelectrodes (n	 4).
At the beginning of seizures, tissue oxygen level was transiently
reduced by 27.76% from 76.74 28.14 to 55.44 22.43 mmHg
(p	 0.07, Wilcoxon) and, because of vasodilation (Fig. 2B), was
quickly (within 158.5  24.83 s) increased to 134.66  44.14
mmHg, gradually returning to baseline (81.48  32.7 mmHg)
after seizure termination. Thus, a relatively mild and brief reduc-
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Figure 2. BBB dysfunction after focal cortical seizures and excess glutamate. A, ECoG recordings from an anesthetized rat before (ACSF) and after topical 4-AP application (4AP). After 60min
under 4-AP exposure, recurrent seizures were recorded. B, Seizure activity was accompanied by an increase in vessel diameter (10.05 1.01%, n	 8, p	 0.01). C, Fluorescence imaging before
(ACSF) and 70min after 4-AP (4AP 70) showing extravascular dye, indicative of BBB dysfunction.D, The effect of recurrent seizures on the permeability of vessels is noticed by EB (seeMaterials
and Methods) extravasation in the treated hemisphere alone. E, BBB permeability maps (color codes for the extent of permeability) depicting the effect (Figure legend continues.)
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tion of tissue oxygen ruled out ischemia in 4-AP/PTX-treated
cortices as the cause for barrier dysfunction.
Excessive glutamate release enhances vascular permeability
Hypersynchronization and activation of large neuronal popula-
tions is associated with a massive release of the excitatory neu-
rotransmitter glutamate(Bradford, 1995). In cultured brain
endothelial cells, the expression of glutamate receptors has been
reported (Krizbai et al., 1998; Sharp et al., 2003; Andra´s et al.,
2007), and exposure to glutamate (1 mM) resulted in NMDA
receptor (NMDA-R)-mediated reduction in the levels and cellu-
lar redistribution of the tight junction protein occludin, as well as
in lower electrical resistance (Sharp et al., 2003; Andra´s et al.,
2007). To test the hypothesis that excess glutamate mediates BBB
dysfunction in vivo, we directly perfused the cortex of anesthe-
tized rats (single dose of ketamine and xylazine, followed by in-
haled isoflurane tominimizeNMDA-R antagonism by ketamine;
Bankstahl et al., 2008) with increasing concentrations of gluta-
mate (0.01–1 mM). To exclude indirect effects of glutamate via
neuronal activation, we blocked neuronal firing and main excit-
atory and inhibitory GABAergic synaptic transmission using
TTX, CNQX, and PTX, respectively. ECoG was recorded simul-
taneously to confirm reduction in neuronal activity and to ex-
clude the induction of seizures under these experimental
conditions (data not shown). Local exposure of the neocortex to
glutamate increased vessel permeability in a dose-dependent
manner that reached significance at 1 mM (18.15 5.9%, n	 9,
p	 0.02, Wilcoxon; Figs. 2G,H, 3A). Glutamate application was
not accompanied by a significant change in vessel diameter
(3.12 2.24%, p	 0.16, Wilcoxon; data not shown).
To test whether the increase in endothelial permeability was
attributed to NMDA-R, experiments were repeated with cortical
perfusion of NMDA (1 mM) and with glutamate in the presence
of the NMDA-R antagonist D-AP-5 (50 M). Although NMDA,
similar to glutamate, increased vessel permeability (18.44 
7.58%, n 	 5, p 	 0.04, Wilcoxon; Fig. 3A), in the presence of
D-AP-5, glutamate had no effect on vessel permeability (3.81
4.34%, n 	 5, p 	 0.22, Wilcoxon; Fig. 3A). In control experi-
4
(Figure legend continued.) of recurrent seizures. F, Averaged change in BBB permeability
during seizures. G, Permeability maps in response to the application of glutamate for 30 min
(glut 1 mM, 30). H, Dose response showing a gradual change in the permeability of vessels
attributable to increased concentrations of glutamate (1 mM, p	 0.02, n	 9). *p 0.05.
Figure3. Mechanisms underlying glutamate-inducedBBBopening.A, Change in the permeability of vessels under different experimental conditions: cortical glutamate application (1mM, glut),
NMDA application (1 mM, NMDA), the addition of D-AP-5 (0.05 mM, glutD-AP5), and ACSF exposure only (ACSF). B, PCLM (Cellvizio Dual Band; Mauna Kea Technologies) of a rat neocortex, after
intravenous injection of EB (see Materials and Methods) and topical application of the calcium indicator OGB (see Materials and Methods). Calcium signal was assessed in the vicinity of microvas-
culature (white dashed line). C, PCLM of the rat neocortex after intravenous injection of EB and topical application of DAF-FM. NO signal was assessed in the vicinity of microvasculature. D, Rise in
calcium signal (OGB) is shown after the drop application of glutamate (1mM). E, Rise in NO signal (DAF-FM) is shown after the drop application of glutamate (1mM). F, Mean calcium and NO signal
(OGB and DAF-FM, respectively) shift in response to glutamate drop application at 1 mM. *p 0.05, **p 0.01.
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ments, brains were exposed to ACSF for 60–120 min, and no
significant change in permeability was measured, excluding a
time-dependent increase in permeability (“ACSF,” 5.11 
3.07%, n	 16, p	 0.7, Wilcoxon; Fig. 3A). Because NMDA-Rs
conduct calcium ions, we used the calcium-sensitive fluorophore
OGB (Fig. 3B, see Materials and Methods) to follow changes in
calcium levels in the close surroundings of microvasculature in
response to drop application of glutamate (0.01–1 mM). Using
image processing of PCLM, we confirmed a long-lasting (12.5
1.3 s) increase in endothelial intracellular calcium after a drop
application of glutamate (n	 5, p 0.01,Wilcoxon; Fig. 3D,F).
These findings suggest that, even in the absence of neuronal fir-
ing, exposure of brain microvasculature to glutamate results in
NMDA-R-mediated increase in intracellular calcium and perme-
ability. Increased intracellular calciumwithin brain endothelium
has been shown to activate NO synthase that generates the free
radical NO (De Bock et al., 2013). NO activates guanylyl cyclase,
leading to the production of cyclic guanosine monophosphate,
cytoskeletal reorganization, and reorganization of tight junction
proteins (De Bock et al., 2013). Therefore, we measured NO us-
ing the fluorescent sensor DAF-FM. Glutamate drop application
(1 mM, in the presence of neuronal blockers) induced a signifi-
cant increase in NO aroundmicrovessels (17.03 3.85%, n	 3,
p	 0.03, Wilcoxon; Fig. 3C,E,F).
Therapeutic implications:
preclinical studies
Because excess glutamate release is a hall-
mark of hypoxic–ischemic injuries (Ben-
veniste et al., 1984; Rothman and Olney,
1986; Nishizawa, 2001) and because the
dynamic progression of BBB dysfunction
has been characterized in the rat cerebral
cortex stroke photothrombosis model
(Schoknecht et al., 2014), we tested the
hypothesis that blocking NMDA-R acti-
vation could reduce BBB breakdown in
the peri-ischemic brain. A focal ischemic
lesion was induced under ketamine/xyla-
zine anesthesia by photothrombosis after
an injection of RB (Watson et al., 1987;
Prager et al., 2010; Schoknecht et al., 2014;
Fig. 4A) in the presence or absence of the
specific NMDA-R blocker D-AP-5. The
spatial progression of BBB dysfunction in
the peri-ischemic region was significantly
reduced in the presence of D-AP-5 at 30
and 60min after clot induction (p	 0.03,
Mann–Whitney; Fig. 4B,C). Another
therapeutic implication of our findings is
the potential induction of BBB opening
for drug delivery. We thus tested whether
the release of glutamate associated with
synchronous neuronal activation using
rTMS could increase barrier permeability
and facilitate drug delivery into the brain.
After 1 Hz stimulation to the anesthetized
(ketamine/xylazine) rat, vascular permea-
bility was significantly increased (18.52
6.54%, n	 11, p	 0.006, Wilcoxon; Fig.
5A,B). This effect was milder and did not
reach a significant level with 10 Hz stimu-
lation (6.93  4.22%, n 	 8, p 	 0.21,
Wilcoxon; Fig. 5B). No change in perme-
ability was observed after sham stimulation (“sham,” 0.8 
1.86%, n	 14, p	 0.59, Wilcoxon; Fig. 5B). That rTMS effect is
mediated through neuronal activation was confirmed by show-
ing that, in the presence of neuronal activity and synaptic trans-
mission blockers, rTMS failed to increase vascular permeability
(2.66  2.33%, n 	 6, p 	 0.92, Wilcoxon; Fig. 5B). To test
whether rTMS-induced increase in permeability may be used for
expediting drug delivery into the brain, we tested the effect of
peripherally administered penicillin on neuronal activity. Peni-
cillin is a GABAA receptor antagonist, and, when directly applied
to the brain, it blocks inhibitory transmission and increases net-
work excitability and often induces seizures (Elger and Speck-
mann, 1983). However, in the presence of an intact BBB,
peripheral administration of low dose of penicillin in the rat has
only a moderate effect on brain activity (Fishman, 1966; Fariello,
1976). We thus used ECoG recordings in the presence of the
intravenous administration of penicillin as a functional measure
for penicillin brain penetration. Whereas under control condi-
tions penicillin only mildly elevated ECoG power (10–40 Hz,
140.29 62.2%, n	 5), repeated injection of the drug after 1 Hz
rTMS stimulation protocol resulted in a significantly increased
ECoG power (10–40 Hz, 334.96  185.77%, n 	 5, p 	 0.04,
Wilcoxon; Fig. 5C,D). A second penicillin injection with no TMS
did not result in increased ECoG power (37.97  167.07%
Figure 4. BBB disruption in the peri-ischemic cortex is prevented by the NMDA-R antagonist D-AP-5. A, The development of a
photothrombosis (PT; see Materials and Methods) as imaged using intravital microscopy after the injection of NaFlu (red arrow
indicates damaged vasculature). Increased vessels’ permeability (NaFlu leakage) is observed in the peri-ischmic cortex at 60 min
follow-up (PT 60, ACSF). B, The peri-infarct. Perfused cortex with abnormal permeability is color coded. C, Averaged percentage
increase in permeability in the peri-infarct cortex at 30 and 60 min after PT shows a marked increase in permeability in control
(ACSF) rats (n	 9, p	 0.008, Wilcoxon) compared with a nonsignificant change in animals exposed to PT in the presence of the
NMDA-R antagonist D-AP-5 (n	 7, p	 0.13, Wilcoxon). **p 0.01.
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from the first injection, n	 4), ruling out that the observed effect
was attributable to repeated drug injections. rTMSon its ownwas
not associated with enhanced brain activity (3.57  8.11% at
10–40 Hz, n 	 3; Fig. 5D), ruling out the possibility that rTMS
underlies the observed lasting increase in neuronal excitability.
These experiments suggest that rTMS-induced BBB opening is
associated with facilitated delivery of penicillin to the neural
tissue.
rTMS increases BBB permeability in human patients
Based on our preclinical experiments, we performed a pilot clin-
ical study designed to examine the effects of rTMS on barrier
integrity in 15 patients with malignant glial tumors (GBM, grade
IV). All patients participated in our study at least 6 months after
tumor resection (patient characteristics are listed in Table 1).
dTMS (1 Hz) was applied using standard protocols (Zangen and
Hyodo, 2002; Zangen et al., 2005; Roth et al., 2007) directed to the
peritumoral brain region (see Materials and Methods). None of
the patients presented adverse events attributable to stimulation.
BBB permeability was quantified, immediately after stimulation,
usingDCE-MRI (Fig. 6; seeMaterials andMethods; Chassidim et
al., 2013, 2015; Veksler et al., 2014) Dynamic T1 data was calcu-
lated and a linear curve was fitted (seven time points, 3–21 min
after entry to the scanner), generating a slope value for each voxel
(“slope map”; Fig. 6A–C). A negative slope indicated normal
washout of the contrast agent from the vascular compartment,
whereas a positive slope suggested accumulation of the contrast
agent in areas with absent or compromised BBB. Method valida-
tion was achieved by demonstration of the following: (1) positive
slopemeasured in tissues lacking BBB (e.g., extracranial muscle);
Figure 5. rTMS induces BBB opening and facilitates drug delivery to the rat cortex.A, Spatial permeabilitymapping showing the effect of 1 Hz rTMS onBBB permeability.B, Averaged percentage
change in the permeability of vessels after rTMS at 1 Hz ( p	 0.006, n	 11) and 10 Hz stimulation. Note the lack of permeability change in control experiments (“sham”) and in the presence of the
Na channel blocker TTX and synaptic transmission blockers (1Hzblockers). C, ECoG recordings in an anesthetized rat before (control, left), after intravenous administration of penicillin (0.833
MU/kg, penicillin,middle), andwith the combinationof intravenouspenicillin and rTMS (penicillin& rTMS, right). Theadministrationof penicillin generates a rise in amplitudeand frequencyof brain
activity, whichwas intensified, when followed by rTMS.D, Spectral analysis of ECoG recordings under the same experimental conditions. Bar graph shows themean ( SEM) of percentage change
in signal power (10–40 Hz, n	 5, p	 0.04). *p 0.05, **p 0.01.
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(2) positive slope measured in areas of tumors and surrounding
tissue; and (3) negative slope measured in major blood vessels,
such as the venous sinuses. Threshold for “normal permeability”
was calculated as the 95th percentile of the CDF of the tissue-
masked slope maps of the hemisphere contralateral to the tumor
(after sham stimulation) and of both hemispheres for the control
group (Fig. 6D; seeMaterials andMethods). Permeability change
was compared between twoDCE-MRI scans performed after real
and sham dTMS, randomly assigned within 1 d of each other.
Experimenters and patients were blinded to the choice of real
versus sham. In 10 of 15 patients, we found a significant increase
in brain enhancement slope values after real comparedwith sham
dTMS, indicating increased barrier permeability to Gd-based
contrast agent after dTMS (Fig. 7A). Enhancementmaps display-
ing the percentage difference between real and sham sessions
show that maximal difference was found in the stimulated tumor
bed region. However, significant changes were also observed in
the peritumoral and ipsilateral brain, as well as in the contralat-
eral hemisphere (Fig. 7B–E). In the 10 patients showing effect of
stimulation, a right shift of the CDF of permeability values was
observed compared with averaged values after sham stimulation,
indicating above-normal vascular permeability (Fig. 7F). Over-
all, increased permeability was found in the tumor bed in nine
subjects and in the peritumoral area in seven subjects, and in
eight subjects, increased permeability was also found in the more
distant ipsilateral and contralateral hemispheres.
Discussion
The BBB is the hallmark of normal brain vascularization, en-
abling the unique extracellular neuronal environment essential
for its proper function. Vascular pathology and dysfunctional
BBB are common in brain diseases, particularly described in isch-
emic and traumatic brain injuries (Prager et al., 2010; Schoknecht
et al., 2014) but also in aging and neurodegenerative disorders
(Mecocci et al., 1991; Montagne et al., 2015), as well as in periph-
eral diseases affecting the brain (e.g., hypertension and diabetes
mellitus; Mooradian, 1997). Increased endothelial permeability
to serum proteins has been found to induce an astrocytic trans-
formation associated with neuroinflammation and impaired
control of the extracellular milieu, neuronal hyperexcitability,
synaptogenesis, and pathological plasticity (Cacheaux et al.,
2009;David et al., 2009;Weissberg et al., 2015). Experimental and
clinical evidence thus support the notion that a compromised
BBB may be associated with dysfunction of the neurovascular
network, cognitive and emotional impairments (Montagne et al.,
2015), seizures and epilepsy (Friedman, 2011), and neurodegen-
eration (Zlokovic, 2008), thus highlighting vascular integrity as a
target for treatment. However, there is lack of knowledge regard-
ing the mechanisms of BBB opening under disease conditions
and no therapeutics available to modulate BBB integrity. For
decades, the intact BBB, as amajor obstacle for drug delivery into
the brain, has been the target of research and clinical trials aiming
to transiently increase its permeability. In the present study, we
show that high concentrations of glutamate, the major excitatory
brain neurotransmitter, directly modulate vascular permeability.
We further demonstrate using confocal microscopy that gluta-
mate enhances calcium influx andNO levels within or adjacent to
microvascular structures, leading to increased vascular permea-
bility through activation of NMDA-R. We demonstrate two
Figure 6. BBB permeability assessment with DCE-MRI analysis in human subjects. A, T1-weightedMRI scan of a patient after tumor resection.B, First and seventh dynamic scans. C, Normalized
slopemap indicating BBB permeability.D, CDFs of the normalized slope values of four control subjects (whole brain, green) and 10 patients after tumor resection in the contralateral hemisphere to
the tumor (blue) and the tumor bed (TB, red). The total CDF of controls contralateral hemisphere to the tumor is in black. Dashed lines indicate the global threshold value of 0.0109, derived from
the 95th percentile of the total CDF. E, Voxels with ST slope values.
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novel therapeutic implications of our findings: (1) that increased
BBB permeability in the peri-ischemic brain (a common finding
in stroke patients and a risk factor for hemorrhagic complication
in the presence of antithrombotic treatment) can be prevented
using NMDA-R antagonists; and (2) that repeated stimulation of
large groups of neurons increases BBB permeability in both ex-
perimental animals and in patients withmalignant brain tumors.
Consistent with previous reports (Librizzi et al., 2012; van
Vliet et al., 2014), we show that the induction of seizures in vivo is
associatedwith an increase in vessel diameter and permeability to
both low- and high-molecular-weight substances (Fig. 2). BBB
dysfunction was not associated with a significant decrease in tis-
sue oxygen levels, and, because of neurovascular coupling, tissue
oxygen levels rapidly increased above baseline, ruling out tissue
hypoxia as a cause for the rapid increase in endothelial permea-
bility during seizures. Prolonged or frequently recurring seizures,
as well as ischemic stroke and traumatic brain injury, are associ-
ated with increased concentrations of extracellular glutamate
(
50-fold increase and in the 0.1–1 mM range; Benveniste et al.,
1984; Rothman and Olney, 1986; Bradford, 1995; Nishizawa,
2001; Parfenova et al., 2006). Our data, showing that a greater
TMS-mediated increase in permeability is prevented when neu-
ronal activity is blocked, but not when glutamate is applied,
suggests that neuronal release of glutamate is targeting a non-
neuronal target. Interestingly, in the absence of neuronal activity,
glutamate did not induce an increase in vessel diameter, suggest-
ing different mechanisms underlying the coupling between neu-
ronal activity to vascular diameter response and permeability.
The observations that direct application of NMDA similarly en-
hances permeability and that permeability increase is blocked in
the presence of NMDA-R blockers (Fig. 3A) indicate that the
effect of glutamate is mediated by NMDA-R. Whether intracel-
lular calcium increase is required for enhanced permeability is
not known. Preventing intracellular calcium elevation using cal-
cium chelators is not feasible in vivo because of massive vasocon-
striction and ischemia (data not shown). However, the observed
increased intracellular calcium and NO in the proximity of mi-
crovasculature in response to glutamate is consistent with in vitro
data showing that NMDA-mediated increased endothelial per-
meability is dependent on increased intracellular calcium within
endothelial cells that leads to free radical formation (Krizbai et al.,
1998; Sharp et al., 2003, 2005). Nevertheless, we cannot rule out a
role for components of the neurovascular unit in close proximity
to endothelial cells, including astrocytes and pericytes (Car-
Figure 7. dTMS induces increase in BBB permeability in patients with malignant glial tumors. A, BBB permeability maps superimposed on T1 brain MR images in a representative patient after
shamandTMS sessions. Color-codedvoxels represent only thosewith abnormally high slope (permeability) values (ST; seeMaterials andMethods).B, Percentageof change in apparent permeability
values for the patient shown in A. Graphs showing percentage of voxels within the ipsilateral hemisphere with abnormally high permeability after sham and real dTMS. C, Brains were manually
segmented (left) to subregions reflecting the tumor bed (TB, red), peri-tumoral brain (PT, green), and ipsilateral (ipsi, blue) and contralateral (contra, yellow) hemispheres.D, Averaged percentage
change in permeability (slope values) in real versus shamstimulationwas calculated for each subregion (tumor bed,p	 0.01; peri-tumor, p	 0.05; ipsilateral, p	 0.01; contralateral, p	 0.009).
Note that, although in all regions TMShada significant effect,maximal changewas found in the tumor bed (n	10patients).E, Percentage change in thenumber of ST voxels (reflecting abnormally
high permeability; see Materials and Methods) is plotted for each subregion. F, CDFs of apparent permeability (slope) values in the different subregions under sham (S) and real (R) dTMS for 10
patients. Note the shift of the curves to the right indicating increased number of voxels with high permeability values, in all regions, most prominently in the tumor bed. *p 0.05, **p 0.01.
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mignoto and Go´mez-Gonzalo, 2010). The intracellular signaling
leading to enhanced permeability is also not clear and may in-
volve reorganization (De Bock et al., 2013) and/or downregula-
tion of tight junction elements (Andra´s et al., 2007). The latter
seems unlikely with the relatively short time delay between insult
(seizure/stroke) and enhanced permeability.Modulation of tran-
scellular transport mechanisms (e.g., Intercellular adhesionmol-
ecule mediated; Yang et al., 2005) may also be involved. Cortical
injury and associated glutamate release has been shown to induce
spreading depolarizations. Interestingly, spreading depolariza-
tion has been associated with BBB opening through the upregu-
lation of matrix metallopeptidase 9 (Gursoy-Ozdemir et al.,
2004). Although spreading depolarization can be induced even in
the presence of TTX (Aitken et al., 1991) and cannot be ruled out
in our experiments (because ECoG recordings were performed
with a bandpass of 10–40Hz), it is unlikely that glutamate appli-
cation in the concentration range used in the present study in-
duced spreading depolarization. In addition, the rapid increase in
permeability we observed (30 min) in the presence of seizures,
photothrombosis, or glutamate application is much shorter than
reported for spreading depolarization (3–6 h; Gursoy-Ozdemir
et al., 2004).
Brain insults, including hypoxic–ischemic or traumatic inju-
ries, were shown to be associated with synchronous neuronal
hyperexcitability and elevated extracellular glutamate in both an-
imal models and humans (Benveniste et al., 1984; Rothman and
Olney, 1986; Nishizawa, 2001). Interestingly, althoughNMDA-R
antagonists were consistently shown to be neuroprotective in an-
imalmodels of brain injuries (Rao et al., 2001;Miguel-Hidalgo et
al., 2002; Huang et al., 2015), their effects on brain vasculature
have never been carefully tested. We propose that at least part of
the protecting effect of NMDA-R blockers may be attributable to
their therapeutic effect to reduce BBBbreakdownwithin the peri-
ischemic/peri-injured brain. However, other non-neuronal
mechanisms, including downregulation of cytokines and re-
duced injury-induced inflammation (Jander et al., 2000), may
contribute to the observed effect. The failure of NMDA-R antag-
onists as neuroprotectants in clinical trials (Morris et al., 1999;
Ikonomidou and Turski, 2002) might be attributable to variabil-
ity between patients in the extent of BBBdamage (Friedman et al.,
2014). This testable hypothesis calls for BBB imaging in patients
with brain insults and follow-up of NMDA-R effects on vascular
integrity and clinical outcome in specific subgroups of patients.
As part of this study, we used recently established DCE-MRI
protocols (Weissberg et al., 2014) to quantify changes in BBB
permeability in patients after sham or real TMS stimulation with
the goal to validate and quantify (for the first time) increased
barrier permeability in response to manipulation. Previous at-
tempts to increase drug delivery included intra-arterial adminis-
tration of mannitol in combination with a chemotherapeutic
agent. This approach has not become a routine practice mainly
because of poor patient tolerance, difficulty to perform repeat-
edly, and lack of confidence in treatment efficacy (Phurrough et
al., 2007). We recruited patients with malignant brain tumors to
test the clinical feasibility and potential realization of our animal
data. Patients with GBM were chosen given the medical need for
enhanced delivery of chemotherapeutics into the brain. For the
first time, we report the use of quantitative DCE-MRI to confirm
a therapeutic modulation of vascular permeability in an individ-
ual patient. TMS may thus become the first approach for a non-
invasive and safe transient BBB opening for drug delivery.
Nevertheless, human data are complex and can indeed be inter-
preted in different ways. The responsiveness of some patients and
not others to stimulation could have resulted from factors asso-
ciated with tumor-related changes in microvasculature, other
treatments (e.g., radiation; Fink et al., 2012), and/or the patients’
medical history and/or general condition. The observation that
stimulation-induced permeability increase was larger in (and in
the surrounding of) the tumor site, supports tumor-related
changes, including altered vascularization, neovascularization
(Baker et al., 2014; Weber et al., 2014), and/or inflammatory
environment (Raychaudhuri et al., 2007). Interestingly, malig-
nant glioma cells were shown to release glutamate that has been
associated with neuronal toxicity and tumor expansion (for re-
view, see Sontheimer, 2008). Such release is expected to increase
baseline glutamate levels in the peri-tumoral brain that may be
sufficient for abnormal increase in permeability and enhanced
response to stimulation in the vicinity of the tumor. Importantly,
permeability increase (to a lower extent) was found significant
even in regions distant from the tumor bed (including the con-
tralateral hemisphere), suggesting that stimulus affected normal
brain vessels as well. Overall, the results from this pilot clinical
study stress the translational potential and feasibility of stimulus-
induced transient BBB opening in the clinical scenario. Future
preclinical studies and clinical trials are awaited to test TMS ef-
fects on the delivery of specific chemotherapeutics and patients’
outcome. Additionally, the features of TMS-induced BBB open-
ing have yet to be fully examined with regards to safety, specifi-
cally the risk of seizures, being the primary concern (Rossi et al.,
2009), in patients with brain tumors (van Breemen et al., 2007).
In summary, we present a novel, neuronal-activity mediated,
NMDA-R-dependent mechanism for the modulation of the per-
meability of brain vasculature. We propose that this mechanism
may be exploited for facilitating BBB closure in neurological dis-
orders and opening in tumor patients to enhance drug delivery.
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